Skip to main content
. 2020 Jul 16;8(2):e000582. doi: 10.1136/jitc-2020-000582

Figure 5.

Figure 5

iMSC/CCL19 local therapy attracts F4/80− CD11c+ CCR7+ DC and increases IFN-γ+ CD8+ T cells iMSC or iMSC/CCL19 were injected i.t. on days 14 and 16 after tumor inoculation. Tumor cells were collected 17 days after tumor inoculation, and tumor-infiltrating immune cells were analyzed by flow cytometry. (A) Representative plots (left) and the percentages of indicated CD11c+ CCR7+ among CD45+ F4/80cells are shown (right). *P<0.05 by Tukey-Kramer test (ANOVA). N.S., not significant. (B) Representative plots (left) and the percentages of CD4+ CD11c+ cells among CD45+ F4/80cells are shown (right). (C, D) CT26 tumor-bearing mice were received i.t. injection with iMSC/CCL19 (arrowheads) and i.p. injection with 100 µg of control IgG or anti-CD4 (depletion) antibody as described in figure 4b. (C) Represent plots (left) and the percentages of CD11c+ F4/80 cells gated on CD45+ cells were shown. (D) The percentages of IFN-γ+ CD8+ T cells among CD3+ T cells are shown (represent plots: left, bar graph; right). **P<0.01 by Tukey-Kramer test (ANOVA). n=3. Splenocytes collected from tumor-bearing mice were analyzed as a control. CCL19, chemokine (C-C motif) ligand 19; IFN, interferon; IgG, immunoglobulin G; iMSC, immortalized MSC; i.p., intraperitoneal; i.t., intratumoral; MSC, mesenchymal stem/stromal cells.